Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and Mortality
The DOI matches its OpenAlex record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
AIM: Add-on therapy with omalizumab, an anti-immunoglobulin E antibody, is effective in improving disease control in patients with allergic asthma of varying severity. The aim of the present study was to determine the efficacy of omalizumab in a subgroup of patients at high risk of serious asthma-related morbidity and mortality. METHODS: A meta-analysis was performed of three randomised, double-blind, placebo-controlled studies (studies 1, 2 and 3) that enrolled 1412 patients with moderate or severe allergic asthma, all requiring daily treatment with inhaled corticosteroids (ICS). Omalizumab was administered subcutaneously every 2 or 4 weeks at a total 4-weekly dose of at least 0.016 mg/kg/IgE [IU/ml]. Each study consisted of a 16-week steroid-stable phase and a 12-16-week steroid-reduction phase, followed by a 24-week extension phase (studies 1 and 2 only). The primary outcome measure was the annualised rate of significant asthma exacerbation episodes (sAEEs) during the steroid-stable phase for the pooled subgroup of 254 high-risk patients (omalizumab, n = 135; placebo, n = 119). sAEEs were those requiring a doubling of baseline ICS dose (studies 1 and 2 only) or use of systemic steroids (all three studies). RESULTS: Overall, the number of patients with at least one sAEE during the steroid-stable phase was reduced from 35% (42/119) with placebo to 18% (24/135) with omalizumab. Mean sAEE rates were 1.56 and 0.69 per patient-year, respectively, a reduction of 56% with omalizumab (p = 0.007). Similar reductions in exacerbations in favour of omalizumab were observed for the whole study period and for all AEEs. In those with a history of hospitalisation in the last year, 6/49 (12%) on placebo vs. 2/44 (4.5%) on omalizumab were re-hospitalised during the study period. Patients treated with omalizumab also showed significantly greater improvements from baseline in PEFR (p = 0.026), overall AQoL (p = 0.042) and mean nocturnal (p = 0.007) and mean total (p = 0.011) asthma symptom scores compared with placebo. CONCLUSIONS: In patients at high risk of serious asthma-related morbidity and mortality, treatment with omalizumab offers the potential to halve the rate of asthma exacerbations and improve disease control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938 · cited 1×
“Total number of patients 135 119 Gender, female:male (n) 81:54 86:33 Mean age (SD) (years) 38 (15) 39 (14) Median BDP dose (μg/day) (range) 800 (500–1200) 800 (400–1200) Median FP dose ( g/day) (range) 1500 (1000–2500) 1500 (1000–2000) Median oral prednisolone dose (mg/day) (range) 10 (2.”
Meta-analysis: Unresolved issues and future developments
Smith, G. D., & Egger, M. (1998) · BMJ · doi:10.1136/bmj.316.7126.221 · Cited by 175
Cited by
Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123
Self-citationOmalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Self-citationLeucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451
Vignola, A. M., Humbert, M., Bousquet, J., Boulet, L., Hedgecock, S., Blogg, M., Fox, H., & Surrey, K. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00550.x · Cited by 405
Self-citation
Metadata
- Authors
- Holgate, S. T., Bousquet, J., Wenzel, S. E., Fox, H., Liu, J., & Castellsagué, J.
- Venue
- Current Medical Research and Opinion
- Publisher
- Taylor & Francis
- Published
- 2001-01-01
- Volume
- 17
- Issue
- 4
- Pages
- 233-240
- ISSN
- 0300-7995 (ISSN-L)
- OpenAlex
- W2108625888
- Cited by
- 126
- References
- 2
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and Mortality. https://app.cochat.ai/papers/10.1185/030079901753403126
- The paper
- Holgate, S. T., Bousquet, J., Wenzel, S. E., Fox, H., Liu, J., & Castellsagué, J. (2001). Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and Mortality. Current Medical Research and Opinion. https://doi.org/10.1185/030079901753403126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.